UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 — Aurora, Colorado

UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 is a clinical research site located in Aurora, Colorado, United States 80045.

Crixeo Clinical Trials Trust Score: 86/100 (GOOD). This profile has not yet been claimed by the site owner.

UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Thyroid Eye Disease.

Sponsors: Tourmaline Bio, Inc., a Novartis Company.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Aurora

Browse all research sites in Colorado · View every site in Aurora

Sponsor Feasibility Report

Trust Score: 86/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101?

UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 has a Crixeo Trust Score of 86/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 conducted?

UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 has 1 clinical trials on record, with 1 currently active. Their work covers Thyroid Eye Disease.

Is UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 accredited by Crixeo Clinical Trials?

UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.